Skip to main content
Premium Trial:

Request an Annual Quote

Evotec Inks Drug Discovery Deal with Shionogi

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec today said that it has signed an agreement to use its Evolution platform to conduct drug discovery services for Japanese pharmaceutical firm Shionogi.

The German drug discovery and development firm said that it will identify for Shionogi small molecule modulators of various protein-protein interaction targets. It will use its Evolution platform, which combines biochemical and biophysical techniques including nuclear magnetic resonance, surface plasmon resonance, and X-ray crystallography, as part of the collaboration.

Financial and other terms were not disclosed.